HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Mucocutaneous Leishmaniasis

A disease characterized by the chronic, progressive spread of lesions from New World cutaneous leishmaniasis caused by species of the L. braziliensis complex to the nasal, pharyngeal, and buccal mucosa some time after the appearance of the initial cutaneous lesion. Nasal obstruction and epistaxis are frequent presenting symptoms.
Also Known As:
Leishmaniasis, Mucocutaneous; Leishmaniases, Mucocutaneous; Mucocutaneous Leishmaniases
Networked: 95 relevant articles (11 outcomes, 13 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Infection
2. Visceral Leishmaniasis (Kala Azar)
3. Acquired Immunodeficiency Syndrome (AIDS)
4. HIV Infections (HIV Infection)
5. Cutaneous Leishmaniasis

Experts

1. Llanos-Cuentas, Alejandro: 2 articles (04/2011 - 06/2007)
2. Boulos, M: 2 articles (08/2000 - 01/2000)
3. Neto, V A: 2 articles (08/2000 - 01/2000)
4. Nicodemo, A C: 2 articles (08/2000 - 01/2000)
5. Badaró, Roberto: 1 article (01/2015)
6. Schooley, Robert: 1 article (01/2015)
7. Gois, Luana: 1 article (01/2015)
8. Grassi, Maria Fernanda Rios: 1 article (01/2015)
9. Celes, Fabiana S: 1 article (10/2014)
10. Borges, Valeria M: 1 article (10/2014)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Mucocutaneous Leishmaniasis:
1. Antimony Sodium Gluconate (Sodium, Stibogluconate)IBA
2. Amphotericin B (Amphotericin)FDA LinkGeneric
3. Interferon-gamma (Interferon, gamma)IBA
4. Allopurinol (Remid)FDA LinkGeneric
5. AntigensIBA
6. AntibodiesIBA
7. liposomal amphotericin BFDA Link
8. Pentamidine (NebuPent)FDA LinkGeneric
9. NifurtimoxIBA
10. meglumine antimoniateIBA

Therapies and Procedures

1. Immunotherapy
2. Drug Therapy (Chemotherapy)
3. Intramuscular Injections
4. Highly Active Antiretroviral Therapy (HAART)
5. Aftercare (After-Treatment)